FIH Partners advises Nordic Capital on acquisition of Evosep, a leading Danish innovator of sample preparation and separation solutions for LC-MS-based proteomics.
Evosep aims to improve quality of life and patient care by radically innovating protein-based clinical diagnostics, initially by collaborating with world-leading scientists to develop new technologies and solutions to make sample separation 100 times more robust and 10 times faster than today’s alternatives. Information about Evosep is available at the company’s website.
FIH Partners acted as exclusive M&A advisor to Nordic Capital on the transaction.
